Embecta Earnings Reports

Embecta delivered a strong Q3 2025, with revenues up 8.4% to $295.5 million and net income significantly increasing to $45.5 million from $14.7 million in the prior year. Adjusted EPS also saw a substantial rise to $1.12. The company successfully completed its ERP system implementation and operationalized new distribution centers, while also tightening and raising its fiscal 2025 outlook.

Embecta experienced a decline in revenue and net income in Q2 2025 compared to the prior year, but improved operating and adjusted EBITDA margins and delivered higher adjusted EPS.

Embecta Corp. reported a decrease in revenue by 5.6% to $261.9 million for the first quarter of fiscal year 2025. The company is progressing with its restructuring plan and brand transition, while also updating its financial guidance to reflect changes in foreign exchange assumptions and raising expectations for certain financial metrics.

Embecta Corp. reported a strong fourth quarter with revenues up 1.5% to $286.1 million. The company is discontinuing its insulin patch pump program and initiating an organizational restructuring plan to streamline operations and reduce costs. They anticipate pre-tax charges of $35 million to $45 million in fiscal year 2025 related to the restructuring plan and expect annualized pre-tax cost savings of $60 million to $65 million.

Embecta Corp. reported a decrease in revenue by 4.8% to $272.5 million for the third quarter of fiscal year 2024. Despite the revenue decrease, the company demonstrated strong gross, operating, and EBITDA margins. They are also tightening and raising their fiscal 2024 outlook for certain financial metrics.

Embecta Corp. reported a 3.6% increase in revenue to $287.2 million for the second quarter of fiscal year 2024. The company is also raising and tightening its fiscal 2024 outlook for key financial metrics.

Embecta Corp. reported a revenue increase of 0.6% to $277.3 million in Q1 2024. The company also progressed on strategic priorities, including the 510(k) filing of its open-loop patch pump with the FDA and raised its guidance for certain key financial reporting metrics.

Embecta Corp. reported a 2.7% increase in revenues to $281.9 million for the fourth quarter of fiscal year 2023. The company's operating income was $25.8 million, and net income was $6.0 million, or $0.10 per diluted share. The company also announced a dividend of $0.15 per share.

Embecta's Q3 2023 revenues were $286.1 million, a decrease of 1.7% on a reported basis and 0.3% on a constant currency basis. The company reported a net income of $15.2 million, or $0.26 per diluted share, compared to $62.4 million, or $1.07 per diluted share, in the prior year period. Adjusted net income was $39.8 million, or $0.69 per diluted share. The company is tightening and raising its fiscal 2023 outlook for key financial metrics.

Embecta Corp. reported a revenue increase of 0.9% to $277.1 million, driven by price and volume increases, and contract manufacturing revenue. The company is raising its guidance for key financial metrics.

Embecta Corp. reported its first quarter fiscal year 2023 financial results, with revenues of $275.7 million, a decrease of 4.7% on a reported basis but an increase of 0.7% on a constant currency basis. The company's performance exceeded initial expectations, and they are raising their guidance for key financial reporting metrics.

Embecta Corp. reported its Q3 2022 financial results, demonstrating resilient commercial performance despite a challenging macroeconomic environment. The company reported revenues of $291.1 million, a decrease of 1.3% on a reported basis but an increase of 2.0% on a constant currency basis. Net income was $62.4 million. The company is reiterating its second half of 2022 fiscal year financial guidance for as-reported revenue growth, and raising its second half of 2022 fiscal year financial guidance for constant currency revenue growth, adjusted gross margin and adjusted EBITDA margin.